# Starlight Cardiovascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/starlight-cardiovascular

- Industry: Medical Devices & Equipment
- Headquarters: San Diego, US
- Website: www.starlightcardio.com
- Total disclosed funding: $9M
- Latest round: Series A (Sep 26, 2022)
- Investors on record: 1

## About

Based in California, US, and founded in 2020 by its CEO Beverly Tang, and co-founders Pedro del Nido, Tom Duerig, Attila Meretei, and Carl Berke, Starlight Cardiovascular, Inc. operates as a preclinical stage medical technology company that develops medical devices to treat pediatric congenital heart defects. In October 2022, Starlight Cardiovascular, Inc. raised USD 9.48 million in series A funding led by Bird B AG a Swiss-based, globally active investment company.

Starlight Cardiovascular, Inc. develops a portfolio of minimally-invasive devices to treat babies born with congenital heart defects, a common birth defects, and the leading cause of infant mortality. The company's first product is a Ductus Arteriosus Stent that replaces a life-saving open chest surgery with a microcatheter-based procedure performed through a small incision in the skin. The product eliminates an open heart procedure for newborns, as well adds a level of safety to the procedure for infants.

The company plans to use the series A funding to support its progress development of its portfolio of pediatric interventional cardiology devices.

## Funding rounds

- Series A, Sep 26, 2022, $9M — Bird B. AG

## Investors

- Bird B. AG (https://capitalatlas.ai/funds/bird-b-ag) — Series A